Medicare numbers trigger physician anger

Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.

Merck looks poised to challenge Gilead

Merck looks poised to challenge Gilead

Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.

Sunshine data highlights major billers

Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Study links patient confidence to Rx adherence

Study links patient confidence to Rx adherence

Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.

Alkermes to submit schizophrenia med this year

Phase-III results prompted the drugmaker to pursue a third-quarter filing.

Lilly's CDK 4/6 inhibitor a cancer contender

Lilly's CDK 4/6 inhibitor a cancer contender

Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.

Pfizer palbociclib news divides investors

Pfizer palbociclib news divides investors

Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.

Health reform spurs Rx growth, data show

Health reform spurs Rx growth, data show

The ACA has spurred double-digit increases in demand for pharmaceuticals, new data suggest.

Sanofi reports on Phase-II PCSK9 trial

The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.

Trials confirm potent efficacy of PCSK9s

Trials confirm potent efficacy of PCSK9s

Detailed Phase-III results from several PCSK9 candidates confirm the clinical ability of the newest class of cholesterol-lowering treatments.

Merck diversifies its Big Data agenda

Merck diversifies its Big Data agenda

Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.

Possible Zohydro competitor surfaces

Possible Zohydro competitor surfaces

A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.

EHR use up 10%, as small practices tame data crunch

EHR use up 10%, as small practices tame data crunch

A report of over 270,000 US medical sites signals that EHR adoption is no longer a luxury reserved for hospitals and health systems.

Prevnar 13 hits goals, but impact is uncertain

Prevnar 13 hits goals, but impact is uncertain

Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.

Adults increasingly using ADHD medications

Adults increasingly using ADHD medications

Express Scripts notes that these prescriptions may not, in fact, be for ADHD.

Nexavar fails recurrence target

Nexavar fails recurrence target

Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.

Study shows sample-drug adherence link

Study shows sample-drug adherence link

A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.

New FDA Twitter feed has diverse following

@openFDA and its related website launched February 27.

AbbVie's all-oral HCV combo shines in trial

AbbVie's all-oral HCV combo shines in trial

Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?

Novartis enhances data access

The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.

FDA approves sNDA for Xeljanz

The new label will reflect the RA pill's superiority to methotrexate and placebo in inhibiting the progression of structural joint damage.

Lilly's GLP-1 contender takes a step forward

Lilly's GLP-1 contender takes a step forward

Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.

Pfizer Prevnar data could boost Rx numbers

Pfizer Prevnar data could boost Rx numbers

The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.

Lilly's ramu' has squamous, non-squamous potential

Lilly's ramu' has squamous, non-squamous potential

The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.

Study finds doctor reviews matter to some extent

Study finds doctor reviews matter to some extent

A report published by JAMA indicated that online reviews sway a percentage of patients, but that personal recommendations hold more weight.

Janssen signs onto Yale data-sharing project

The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.

Pitting Big Data against nonadherence

Pitting Big Data against nonadherence

A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.

Ph.III results a boost for Amgen in PCSK9 race

Ph.III results a boost for Amgen in PCSK9 race

Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.

IMS to go public, says acquisitions possible

IMS to go public, says acquisitions possible

The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus that it anticipates future acquisitions.

Amgen bone-builder bests older meds: trial

Amgen bone-builder bests older meds: trial

Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

Kalydeco misses trial endpoint, though some benefit

Kalydeco misses trial endpoint, though some benefit

Kalydeco failed to hit its primary endpoint of significantly improving lung function in a subset of CF patients, but some did show a benefit.

Data arm Gilead for next stage of HCV race

Data arm Gilead for next stage of HCV race

Sovaldi is already approved for most patients with HCV, but its marketer may have earned itself some breathing room against rivals in the next stage of the all-oral hep. C arms race.

Patients sound off on helping pharma find new molecules

Patients sound off on helping pharma find new molecules

A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.

Sanofi's heir to Lantus meets endpoint in trials

Sanofi's heir to Lantus meets endpoint in trials

Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.

ADHD rise spurs diagnostics firms

ADHD rise spurs diagnostics firms

Research suggests ADHD is becoming a regular fixture in adolescence. At the same time, publishers and startups have developed increasingly complex tools to separate patients from abusers.

Poll: Statin use will grow modestly

Poll: Statin use will grow modestly

A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.

E-prescribing systems not so pharma friendly

E-prescribing systems not so pharma friendly

A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.

Amgen PCSK9 drug passes safety test

New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.

Small patient majority supports risky Sanofi MS drug: poll

Small patient majority supports risky Sanofi MS drug: poll

Most patients would advise today's FDA Lemtrada panel to allow doctors to gauge the drug's risk-benefit profile, although there was strong sentiment on either side of the issue.

GSK misses on late-stage CV drug

GSK misses on late-stage CV drug

An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.

Lemtrada's future in doubt after reviewers flag safety issues

Lemtrada's future in doubt after reviewers flag safety issues

Safety reviewers' reservations about the MS drug's risk profile, unveiled in briefing documents ahead of an ad-com meeting, suggest it won't be smooth sailing for the drug in the US.

Genotype-1 hep. C race heats up

Genotype-1 hep. C race heats up

Data released at the Boston meeting of the American Association for the Study of Liver Diseases hints at an upcoming Gilead-Merck brawl.

Health apps come up short in study

Health apps come up short in study

Researchers found that most healthcare apps have limited functionality, don't serve patients with multiple needs, and taper off when support is needed most. No wonder adoption is low.

Study says DPP-IV benefits may go beyond diabetes

Researchers say the drug class could be linked to a lower autoimmune risk among diabetics.

Pediatricians want greater condom access

The AAP says greater access and education are critical in curbing STIs.

FDA panel endorses Gilead, Janssen hep. C drugs

It was a 15-0 vote for Gilead's sofosbuvir in hep. C. The expedited PDUFA date: Dec. 8. Janssen's simeprivir was endorsed the day before.

Mobile makes users more likely to switch brands: survey

Mobile makes users more likely to switch brands: survey

Smartphone users, while in the exam room, are more apt to be in "switch mentality," a study finds.

Good news/bad news for Merck's pipeline

Word came of Breakthrough Designation for an HCV hopeful, a day after a hiccup in a heart drug trial.

Poll suggests oncologists already using GSK melanoma drugs off-label

A report says oncologists may be using GSK's Tafinlar and Mekinist together in a non-FDA approved combination therapy.

Positive data for Eylea in branch form of occlusion

On Monday Regeneron reported more positive Ph. III data for its wet AMD/macular edema drug Eylea (aflibercept).

Do depot drugs really deliver?

Do depot drugs really deliver?

In schizophrenia, non-compliance can be disastrous. Do depot drugs really make a difference for patients?

Xeljanz line extension could lift drug's profile

Xeljanz line extension could lift drug's profile

An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.

Report zeroes in on costliest patients

Five percent of the patient population accounts for 50% of US healthcare costs, one deep dive shows. A major problem: access to medical care.

Racial gap still wide for use of statins, painkillers

Racial gap still wide for use of statins, painkillers

Recent studies underscore a need for greater engagement in multicultural communities.

Rebound seen in HCP meeting turnout: report

Rebound seen in HCP meeting turnout: report

Attendance by physicians crept up in 2012, said the trade group HCEA, but overall turnout was flat, likely because exhibitors brought less personnel along to meetings.

Retail pharmacies up consumer satisfaction

Retail pharmacies up consumer satisfaction

A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.

GSK and nonprofit shrink Big Data down to size

GSK and nonprofit shrink Big Data down to size

The partnership seeks to improve medication adherence through predictive analytics.

Patient power taking center stage at event

Patient power taking center stage at event

An upcoming leadership summit is devoted to exploring whether health social media is driving meaningful change, as well as new ways to engage with health activists.

Could EHR incentives draw pharma into exam room?

Could EHR incentives draw pharma into exam room?

How potential alignment between drug companies and physicians, via the EHR, could extend brand reach.

Study reveals doc detail preferences: Hang up the phone

Study reveals doc detail preferences: Hang up the phone

Doctors shared their information preferences with CMI/Compas, revealing ways marketers can better pace their communications to max out channels.

CMS projects healthcare spending to rise

CMS projects healthcare spending to rise

Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards

Pharmacists often give nod on meds: survey

Pharmacists often give nod on meds: survey

Pharmacists are surprisingly open to rep visits, are often online at work, and are making slightly more drug recommendations than the year before, findings show.

Researchers propose new Rx adherence model

Researchers propose new Rx adherence model

Researchers say using additional data points offers greater insight into patient-adherence patterns.

Breast cancer risk awareness shown lagging

Researchers surveying 21 Long Island mammography centers found that women do not know their risk.

Pharma fixed in online traffic patterns, despite distrust: survey

A good percentage of consumers are open to visiting a pharmaceutical company website, an online survey shows, despite a persistent undercurrent of distrust for industry.

Blogs may smooth ups, downs of breast cancer: study

For women suffering from breast cancer, online tools appeared to be helpful in battling depression, a randomized trial showed.

Game for cancer patients gets mobile app

Game for cancer patients gets mobile app

Re-Mission, the video simulation known to change young patients' attitudes toward cancer, is in its second iteration. And one big drug maker has added its backing.

CDC finds the sleepless and educated use Rx aids

CDC finds the sleepless and educated use Rx aids

The Centers for Disease Control and Prevention profiles the typical sleep aid user, and finds that eight hours does not mean consumers are sleeping without help.

Rampant dissatisfaction with psoriasis drugs: study

Rampant dissatisfaction with psoriasis drugs: study

Sales may be rising, but a new study finds current psoriasis therapies leave room for improvement. Over half of patients said they want better options.

Cholesterol market still poised for growth through 2022: study

Despite a gradual loss from generics, new treatments are expected to keep sales trending upward

GSK clears another flu vaccine, but patients may not be buying

GSK clears another flu vaccine, but patients may not be buying

The FDA approved GlaxoSmithKline's second quadrivalent flu vaccine, but a CVS study indicates that consumers are big fans of the vaccination, as long as they aren't the ones rolling up their sleeves.

Eylea outduels Lucentis for physician mindshare, survey shows

Eylea outduels Lucentis for physician mindshare, survey shows

Data show doctors are increasingly leaning on Regeneron's Eylea over Roche's Lucentis, as the two battle for share of the wet-AMD market.

Mixed results underscore orphan launch hurdles

Early sales of NPS's Gattex have soared, while those of Protalix's Elelyso have been sluggish, underscoring the challenges of rare-disease launches.

NY'ers to get first taste of Big Data, as creation of state's patient portal gets under way

NY'ers to get first taste of Big Data, as creation of state's patient portal gets under way

The state's first patient portal has officially entered development, and the e-health firm leading the effort said that a former WebMD executive joined its board.

Business briefs: Sanofi, GlaxoSmithKline, AllTrials

Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals

Oncologists still most likely to rebuff sales reps: study

Oncologists still most likely to rebuff sales reps: study

Oncologists have the most restrictive access policies, a study shows for the second year in a row. But it's not impossible to book face time with these clinicians.

"Sensor you swallow" passes psych test

"Sensor you swallow" passes psych test

Proteus Digital Health's ingestible sensor shows utility as an adherence tool for those on psych meds, a study suggests.

HPV vaccination rates losing ground, CDC reports

The CDC says HPV vaccination rates are not improving. The latest data comes just as a recent report shows the vaccine cannot only help fend off cervical cancer, but throat cancers as well.

Doctors could use more info on health exchanges: study

A new survey of doctors reveals how much they know (or don't) about the looming launch of healthcare exchanges.

Branded drug spend up, but slower growth ahead

Last year, a wave of new products brought the industry succor as it awaits the full impact of the patent cliff on blockbuster brands. But companies should brace for contraction.

Email Newsletters